Historical record - last NADAC effective date: 2/21/2024
Product Information
ESZOPICLONE 2 MG TABLET is a generic product labeled by Sun Pharmaceutical Industries Inc., priced at $0.1140 per EA under NDC 47335058788. Its NADAC has been published 506 times since Jun 18, 2014.
FDA first approved this application on Apr 3, 2013. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the ESZOPICLONE market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
2 mg/1
Manufacturer
Sun Pharmaceutical Industries Inc.NDC
47335058788
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
2/21/2024
Active Ingredients
ESZOPICLONEApproval Type
Generic (ANDA)
FDA Application
ANDA091103FDA Approved
4/3/2013
TE Code
AB
On Market Since
4/15/2014
Price Statistics
The NADAC for ESZOPICLONE 2 MG TABLET has been published 506 times since Jun 18, 2014, and over the history we have for it it has declined 88.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1140 per EA |
|---|---|
| All-time high | $0.9669 (Jul 16, 2014) |
| All-time low | $0.0984 (Feb 22, 2023) |
| Median price | $0.2353 |
| Average price | $0.3144 |
| Largest weekly change | +44.2% (Sep 18, 2019) |
| Weeks tracked | 506 |
| Tracking since | Jun 18, 2014 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
+10.8%
5Y
-50.3%
All
-88.2%
Last surveyed Feb 21, 2024 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 20% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Sun Pharmaceutical Industries Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ESZOPICLONE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ESZOPICLONE 2 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ESZOPICLONE 2 MG TABLET, manufactured by Sun Pharmaceutical Industries Inc., is $0.1140 per EA (NDC 47335058788), effective Feb 21, 2024.
How has the price of ESZOPICLONE 2 MG TABLET changed over time?
Over the history we have for it, the NADAC for ESZOPICLONE 2 MG TABLET has declined 88.2%. It has been tracked across 506 weekly CMS publications since Jun 18, 2014.
What are the highest and lowest recorded NADAC prices for ESZOPICLONE 2 MG TABLET?
Since Jun 18, 2014, the NADAC for ESZOPICLONE 2 MG TABLET has ranged from a low of $0.0984 (Feb 22, 2023) to a high of $0.9669 (Jul 16, 2014), with a median of $0.2353 per EA.
Are there cheaper alternatives to ESZOPICLONE 2 MG TABLET?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ESZOPICLONE 2 MG TABLET, is $0.0910 per EA — about 20% below ESZOPICLONE 2 MG TABLET.
Who manufactures ESZOPICLONE 2 MG TABLET?
ESZOPICLONE 2 MG TABLET (NDC 47335058788) is labeled by Sun Pharmaceutical Industries Inc., and CMS classifies it as a generic product.